Molecular Genetics Studies of Cancer Patients and Their Relatives
Launched by CITY OF HOPE MEDICAL CENTER · Dec 3, 2019
Trial Information
Current as of July 23, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, titled "Molecular Genetics Studies of Cancer Patients and Their Relatives," is looking into how both genetic and lifestyle factors might contribute to the development of certain cancers. Researchers want to understand how these factors can impact the outcomes for patients who have a personal or family history of cancer. The study is currently recruiting participants of all ages and genders who have had cancer themselves or have close family members with cancer, especially if there are signs that the cancer could be inherited. This might include situations like being diagnosed with cancer at a young age, having multiple types of cancer in the family, or having rare cancer types.
If you or a family member are interested in participating, you may be eligible if you meet certain criteria, such as having a personal history of cancer or being part of a group known to have a higher risk of genetic alterations. Participants can include adults and children (with parental consent), and even deceased individuals can be included if their family provides consent for medical records. Throughout the study, participants can expect to share their family history of cancer and may provide samples for genetic testing. This research aims to help improve our understanding of cancer and potentially guide future prevention and treatment strategies.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- * Individuals must have a personal history of cancer and/or a family history of cancer suggestive of the presence of an inherited predisposition. This inherited predisposition might manifest as:
- • Young age cancer diagnosis
- • Multiple primary neoplasms in affected member
- • The presence of rare tumor types in the family
- • Congenital malformations
- • Any other family clustering of cancer
- • Any other cancer-predisposing genetic diseases/conditions
- • Individuals may also be eligible by participation in the City of Hope Cancer Screening \& Prevention Program Network (CSPPN) clinical service or on the basis of membership in a group known or suspected to have an increased risk of carrying a genetic alteration or of sustaining a particular exposure that would place that at increased risk of cancer. (Examples would include members of occupational cohorts like asbestos workers, individuals with multiple dysplastic nevi in the absence of a family history of cancer, and individuals descended from a particular tribe in the American Southwest who have an increased incidence of a rare genetic alteration associated with an increased risk of a specific cancer.)
- • Individuals and families may be referred to us in a number of different ways. After initial contact is made with a individual or family by family studies personnel; an individual within the bloodline will be identified as the historian. There may be more than one historian within a family
- • At least one historian must be wiling to provide information or access as needed to contact appropriate family members for documentation of cancer and for consent. An individual is considered to be eligible to participate if they criteria; contact with relatives is not always indicated
- • Individuals who are under 18 are eligible for study if they meet the criteria. Consent for participation must be given by a legal guardian or parent
- • Deceased patients may be included in the study. Public records, such as death certificates, can be used to confirm information from individuals or family members. If medical records are needed, consent for these records will be obtained from the deceased's next of kin. Next of kin refers to the following hierarchy of relatives; spouse, offspring, parents, and siblings. (Any further use of next of kin in this protocol should relate back to this hierarchy.) Archived tissue samples, such as pathology blocks or snap frozen tumor from a pathology department tumor bank (discard specimens) may be used for genetic research
- Exclusion Criteria:
- • A family may be ineligible for study if the historian will not allow access to anyone within the family and thus, the accuracy of the family history cannot be established
About City Of Hope Medical Center
City of Hope Medical Center is a leading research and treatment institution located in Duarte, California, dedicated to advancing innovative therapies and improving patient outcomes in the fields of cancer, diabetes, and other life-threatening diseases. With a strong emphasis on translational medicine, City of Hope combines cutting-edge research with compassionate care, fostering a collaborative environment for clinical trials that aim to bring new treatments from the laboratory to the bedside. The center is recognized for its commitment to patient-centered care and its role as a National Cancer Institute-designated Comprehensive Cancer Center, making it a pivotal player in the landscape of medical research and clinical innovation.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bethesda, Maryland, United States
Lima, , Peru
Chicago, Illinois, United States
Duarte, California, United States
Santa Barbara, California, United States
Laredo, Texas, United States
Los Angeles, California, United States
Amarillo, Texas, United States
Canton, Ohio, United States
Fort Lauderdale, Florida, United States
Houston, Texas, United States
Albuquerque, New Mexico, United States
Cedar Rapids, Iowa, United States
Paoli, Pennsylvania, United States
Concord, California, United States
Fullerton, California, United States
Flemington, New Jersey, United States
West Reading, Pennsylvania, United States
Fond Du Lac, Wisconsin, United States
Waukesha, Wisconsin, United States
Chicago, Illinois, United States
Albuquerque, New Mexico, United States
Boca Raton, Florida, United States
San Juan, , Puerto Rico
Laguna Hills, California, United States
Lubbock, Texas, United States
Orange, California, United States
Brighton, Massachusetts, United States
Bend, Oregon, United States
Roseville, California, United States
Albuquerque, New Mexico, United States
Post Falls, Idaho, United States
Mount Kisco, New York, United States
Cheyenne, Wyoming, United States
Frederick, Maryland, United States
Phoenix, Arizona, United States
Poughkeepsie, New York, United States
Bogotá, Cundinamarca, Colombia
Medellín, , Colombia
Guadalajara, Jalisco, Mexico
Mexico City, Tlalpan, Mexico
Nuevo Leon, , Mexico
Patients applied
Trial Officials
Stephen Gruber, MD
Principal Investigator
City of Hope Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials